2026 — Present
Principal Investigator · Phase I, metabolic / GLP-1
Medical Director and Principal Investigator for a Phase I program studying
safety, tolerability, pharmacokinetics and food effect in healthy, overweight
and obese participants and patients with type 2 diabetes.
2021 — 2023
Principal Investigator · Phase III, respiratory
A 52-week randomized, double-blind, placebo- and active-controlled study
in COPD and chronic bronchitis, carried through to close-out.
2019 — Present
Principal Investigator · Multi-protocol trials
Protocol-lifecycle leadership across metabolic, cardiovascular, and
regenerative therapies, including site initiation, monitoring, and close-out.